Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × donafenib × Endocrine × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Gastrointestinal 1 Endocrine 1

Conditions

Differentiated Thyroid Cancer 1

Interventions

lanreotide 7 Everolimus 7 lutetium Lu 177 dotatate 6 Octreotide 6 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 amino-acid, glucose, and electrolyte solution 3 Thyrotropin Alfa 3 Mitotane 3 Mifepristone 3 Doxorubicin 3 Corlux 3 Capecitabine 3 Cabergoline 3 surufatinib 2 ribociclib 2 pasireotide 2 fluorodopa F 18 2 cabozantinib 2 Temozolomide 2 Receptor-Like Protein Tyrosine Phosphatases, Class 2 2 Iodine-131 2 Introns 2 Injections 2 Ifosfamide 2 Ga(III)-DOTATOC 2 Fulvestrant 2 Filgrastim 2 Etoposide 2 Cisplatin 2 Chemotherapy, Adjuvant 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡